Document Detail


Adherence rates with infliximab therapy in Crohn's disease.
MedLine Citation:
PMID:  16984504     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Inflammatory bowel disease is associated with non-adherence to treatment with oral medications. AIM: To assess the intravenous infliximab adherence rate and identify risk factors for non-adherence to treatment. METHODS: Infliximab infusion dates for 1 June 2002-30 October 2003 were obtained. Additional information was obtained from two other administrative and patient-based databases. Non-adherence was defined as a 'No Show' designation for a scheduled appointment. Non-adherence rate, odds ratios for associations to 'No Show' appointments and analysis were performed to identify patient characteristics associated with non-adherent behaviour. RESULTS: One thousand hundred and eighty-five infliximab infusions were scheduled for 274 patients. Forty-eight (4%) of appointments were classified as 'No Show'. Six patients accounted for 13/48 (27%) of failed appointments; another 35 patients missed one appointment. 'No Show' appointments were more likely to be for female patients, those on concomitant immunomodulators and those >18 weeks from initial infusion. Patients who missed >1 appointment were more likely to be female and have Medicaid vs. those with only one missed appointment (P < 0.05). Indication, patient area code and race were not significantly associated with single or repeated No Show behaviour. CONCLUSIONS: Overall, the non-adherence rate for infliximab is low. Risk factors that may contribute to non-adherence to treatment include female gender and maintenance dosing.
Authors:
S Kane; L Dixon
Related Documents :
16925904 - Effective role redesign: an audit of outcomes following the introduction of a new nurse...
3452374 - Family practice physicians' beliefs, attitudes, and practices regarding obesity.
17145904 - Participation of french general practitioners in end-of-life decisions for their hospit...
18197544 - Patient education: an efficient adjuvant therapy for hyperphosphatemia in hemodialysis ...
21719884 - Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndro...
8416634 - Diagnostic success of bronchoscopic biopsy in immunocompromised patients with acute pul...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  24     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-20     Completed Date:  2007-05-21     Revised Date:  2007-12-03    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1099-103     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Chicago, Chicago, IL 60637, USA. skane@medicine.bsd.uchicago.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Appointments and Schedules
Crohn Disease / therapy*
Female
Humans
Male
Middle Aged
Patient Compliance / statistics & numerical data*
Grant Support
ID/Acronym/Agency:
P30 DK42086/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose...
Next Document:  The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the...